Stage II/III Colorectal Cancer Recurrence

Conditions: Colorectal Cancer, Colorectal Adenocarcinoma, Colorectal Cancer Stage II, Colorectal Cancer Stage III, Colorectal Cancer Recurrent

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Enrollment: 400

Sponsor: City of Hope Medical Center

Summary

This study will develop an assay to predict disease recurrence in patients with stage II/III CRC after receiving adjuvant chemotherapy, using genome-wide DNA methylation.

Eligibility Criteria

Inclusion Criteria: * Stage II (high-risk) or III colorectal cancer (TNM classification, 8th edition). * Received standard diagnostic, staging, and therapeutic procedures as per local guidelines * Received stage-specific curative-intent resection followed by adjuvant chemotherapy. * Confirmed cancer-free survivorship confirmed at the time of study inclusion. Exclusion Criteria: * Lack of written informed consent. * Development of recurrence in the first 6 months following adjuvant chemotherapy completion. * Hereditary colorectal cancer syndromes (identified through genetic testing) * Inflammatory bowel diseases

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06314958). StuddyBuddy aggregates publicly available trial information.